

STIC-EIC1600/2900

274936

From: NELSON BLAKELY III [nelson.blakelyiii@uspto.gov]
Sent: Tuesday, October 14, 2008 9:31 AM
To: STIC-EIC1600/2900
Subject: Search Request, Case/Application No.: 10/581,170

Requester: NELSON BLAKELY III (P/1614)
Art Unit: GROUP ART UNIT 1614
Employee Number:
Office Location: REM 3B69
Phone Number: (571)270-3290

Case/Application number: 10/581,170
Priority Filing Date: 12/03/2003
Format for Search Results: Score
Meaning of unusual acronyms or initialisms:

Identify the novelty:

Additional comments:

Attached you will find an excerpt of the instant specification wherein chemical name and structure are indicated. Thanks!

Attachment: Yes (10581170--StructureSearch.pdf)

10/14/2008

458
-116
=242

LB

=> d ibib abs hitstr l6 1-1

L6 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:523262 HCAPLUS Full-text
 DOCUMENT NUMBER: 143:65409
 TITLE: Pharmaceutical compositions comprising ~~danazol~~
 INVENTOR(S): Holm, Per; Norling, Tomas
 PATENT ASSIGNEE(S): Lifecycle Pharma A/S, Den.
 SOURCE: PCT Int. Appl., 54 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053660	A2	20050616	WO 2004-DK844	20041203
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1691795	A2	20060823	EP 2004-801168	20041203
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
US 20080249076	A1	20081009	US 2006-581170	20060919
PRIORITY APPLN. INFO.:			DK 2003-1785	A 20031203
			WO 2004-DK844	W 20041203
AB	A controlled release pharmaceutical comprising danazol has the property of slow release of danazol over an extended period of time and markedly increased bioavailability compared to com. available danazol -containing products. The pharmaceutical composition comprises danazol dissolved in a solid vehicle or carrier and is especially suitable for oral solid dosage forms. The composition significantly reduces food effect and may reduce side effects. For example, a multiparticulate modified-release granule formulation contained danazol 2.00%, PEG 6000 34.65%, Poloxamer 14.85%, and lactose 48.50%. Granules prepared (250 g) were coated with Surelease to obtain a coating of 50% weight/weight by applying 1 kg of an aqueous 12.5% Surelease.			
IT	9004-65-3, Hydroxypropyl methyl cellulose RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (Metolose 90SH; danazol controlled-release solid oral composition with increased bioavailability)			
RN	9004-65-3 HCAPLUS			
CN	Cellulose, 2-hydroxypropyl methyl ether (CA INDEX NAME)			
CM	1			
CRN	9004-34-6			
CMF	Unspecified			
CCI	PMS, MAN			


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

10/581,170

CM 2

CRN 67-56-1


CMF C H4 O



CM 3

CRN 57-55-6

CMF C3 H8 O2



IT 9004-57-3, Surelease 33434-24-1, Eudragit RS 30D
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coating; ~~danazol~~ controlled-release solid oral composition with
increased bioavailability)

RN 9004-57-3 HCAPLUS

CN Cellulose, ethyl ether (CA INDEX NAME)

CM 1

CRN 9004-34-6

CMF Unspecified


CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

CM 2

CRN 64-17-5

CMF C2 H6 O



RN 33434-24-1 HCAPLUS


CN Ethanaminium, N,N,N-trimethyl-2-[(2-methyl-1-oxo-2-propen-1-yl)oxy]-,
chloride (1:1), polymer with ethyl 2-propenoate and methyl
2-methyl-2-propenoate (CA INDEX NAME)

CM 1

CRN 5039-78-1

CMF C9 H18 N O2 . C1

10/581,170



CM 2

CRN 140-88-5


CMF C5 H8 O2



CM 3

CRN 80-62-6

CMF C5 H8 O2



IT 17230-88-5, Danazol


RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(danazol controlled-release solid oral composition with increased bioavailability)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



IT 63-42-3, Lactose 77-93-0, Eudraflex 109-43-3, Dibutyl sebacate 1318-93-0, Montmorillonite, biological studies 1327-43-1, Magnesium aluminosilicate 7631-86-9, Silicon dioxide, biological studies 9002-89-5, Polyvinyl alcohol 9003-39-8, PVP 9004-32-4 12511-31-8 14987-04-3, Magnesium trisilicate 25322-68-3, Polyethylene glycol 66732-77-2, Saponite 106392-12-5,

10/581,170


Poloxamer 357271-96-6, Sipernat 570 736175-62-5,
Sipernat 360

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(danazol controlled-release solid oral composition with increased
bioavailability)

RN 63-42-3 HCAPLUS


CN D-Glucose, 4-O- β -D-galactopyranosyl- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 77-93-0 HCAPLUS

CN 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, 1,2,3-triethyl ester (CA
INDEX NAME)



RN 109-43-3 HCAPLUS

CN Decanedioic acid, 1,10-dibutyl ester (CA INDEX NAME)



RN 1318-93-0 HCAPLUS

CN Montmorillonite ((Al_{1.33}-1.67Mg_{0.33}-0.67)(Ca₀-1Na₀-1)0.33Si₄(OH)₂O₁₀.xH₂O)
(CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 1327-43-1 HCAPLUS


CN Silicic acid, aluminum magnesium salt (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 7631-86-9 HCAPLUS

CN Silica (CA INDEX NAME)


10/581,170



RN 9002-89-5 HCAPLUS
CN Ethenol, homopolymer (CA INDEX NAME)

CM 1


CRN 557-75-5
CMF C2 H4 O



RN 9003-39-8 HCAPLUS
CN 2-Pyrrolidinone, 1-ethenyl-, homopolymer (CA INDEX NAME)

CM 1

CRN 88-12-0
CMF C6 H9 N O



RN 9004-32-4 HCAPLUS
CN Cellulose, carboxymethyl ether, sodium salt (CA INDEX NAME)


CM 1

CRN 9004-34-6
CMF Unspecified
CCI PMS, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


CM 2

CRN 79-14-1
CMF C2 H4 O3



RN 12511-31-8 HCAPLUS
CN Silicic acid (H4SiO4), aluminum magnesium salt (2:2:1) (CA INDEX NAME)

10/581,170




● Al

● 1/2 Mg

RN 14987-04-3 HCAPLUS
CN Magnesium silicon oxide (Mg₂Si₃O₈) (CA INDEX NAME)

Component	Ratio	Component Registry Number
=====	=====	=====
O	8	17778-80-2
Si	3	7440-21-3
Mg	2	7439-95-4

RN 25322-68-3 HCAPLUS
CN Poly(oxy-1,2-ethanediyl), α -hydro- ω -hydroxy- (CA INDEX NAME)




RN 66732-77-2 HCAPLUS
CN Saponite (Mg₁₈[Al₄O₃(SiO₃)₂₁].6H₂O) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 106392-12-5 HCAPLUS
CN Oxirane, 2-methyl-, polymer with oxirane, block (CA INDEX NAME)

CM 1

CRN 75-56-9
CMF C3 H6 O



CM 2

CRN 75-21-8
CMF C2 H4 O



RN 357271-96-6 HCAPLUS

CN Sipernat 570 (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 736175-62-5 HCAPLUS

CN Sipernat 360 (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT ~~1343-98-2~~, Sipernat 350


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(particles; ~~danazol~~ controlled-release solid oral composition with
increased bioavailability)

RN 1343-98-2 HCAPLUS

CN Silicic acid (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> d que stat l15
L7 STR



NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 25

STEREO ATTRIBUTES: NONE

L9 36 SEA FILE=REGISTRY SSS FUL L7
L10 893 SEA FILE=HCAPLUS ABB=ON L9
L11 135 SEA FILE=HCAPLUS ABB=ON L10 AND ?ENDOMETRIOSIS?
L12 20 SEA FILE=HCAPLUS ABB=ON L11 AND ?DRUG?(W)?DELIVER?
L13 19 SEA FILE=USPATFULL ABB=ON L11 AND ?DRUG?(W)?DELIVER?
L14 39 DUP REMOV L12 L13 (0 DUPLICATES REMOVED)
L15 31 SEA L14 AND (PRD<20031203 OR PD<20031203)

=> d ibib abs hitstr l15 1-31


L15 ANSWER 1 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:467984 HCAPLUS Full-text
DOCUMENT NUMBER: 141:22217
TITLE: Therapy of non-malignant diseases or disorders with
anti-ErbB2 antibodies
INVENTOR(S): Sliwkowski, Mark X.; Brunetta, Paul G.
PATENT ASSIGNEE(S): Genentech, Inc., USA
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004048525	A2	20040610	WO 2003-US37367	20031121 <--
WO 2004048525	A3	20070118		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				

10/581,170

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
 NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
 BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
 ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 CA 2506320 A1 20040610 CA 2003-2506320 20031121 <--
 AU 2003295798 A1 20040618 AU 2003-295798 20031121 <--
 US 20040258685 A1 20041223 US 2003-719310 20031121 <--
 EP 1572972 A2 20050914 EP 2003-787006 20031121 <--
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006516117 T 20060622 JP 2004-555592 20031121 <--
 PRIORITY APPLN. INFO.: US 2002-428027P P 20021121 <--
 WO 2003-US37367 W 20031121 <--
 AB The authors disclose the preparation and biol. activity of murine and
 humanized antibodies to HER2. In one example, an anti-HER2 antibody is shown
 to inhibit heregulin-induced activation of Akt kinase and erbB2 association
 with erbB3. The present application describes treatment of non-malignant
 indications, such as psoriasis, ~~endometriosis~~, scleroderma, vascular diseases
 or disorders, respiratory disease, colon polyps or fibroadenoma, with anti-
 ErbB2 antibodies (e.g. rhuMAb 2C4).
 IT 17230-88-5, Danazol
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (adjunct therapy with antibodies to ErbB2)
 RN 17230-88-5 HCAPLUS
 CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 2 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:353144 HCAPLUS Full-text
 DOCUMENT NUMBER: 140:368700
 TITLE: Methods using exemestane, alone or with other
 therapeutic agents, for treating estrogen-dependent
 disorders
 INVENTOR(S): Wajszczuk, Charles Paul; Gans, Hendrik J. Dekoning; Di
 Salle, Enrico; Piscitelli, Gabriella; Massimini,
 Giorgio; Purandare, Dinesh
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 21 pp., Cont.-in-part of WO
 2002 72,106.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040082557	A1	20040429	US 2003-611653	20030702 <--
WO 2002072106	A2	20020919	WO 2002-EP638	20020118 <--
WO 2002072106	A3	20031030		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:

US 2001-770911	B2 20010126 <--
WO 2002-EP638	A2 20020118 <--
US 2002-393320P	P 20020702 <--

AB The invention discloses a method of preventing and/or treating estrogen-dependent disorders selected from ~~endometriosis~~, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, fibrocystic breast disease and fibrocystic mastopathy, which comprises administering to a female mammal in need of such treatment an effective amount of aromatase inactivator exemestane, alone or in combination with addnl. therapeutic agents. The invention also discloses a method for treating infertility in a female mammal in need of the infertility treatment, comprising administering an effective amount of exemestane to the mammal.

IT 17230-88-5, Danazol


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(exemestane, alone or with other therapeutic agents, for treating estrogen-dependent disorders)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 3 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:922665 HCAPLUS Full-text

DOCUMENT NUMBER: 139:391366

TITLE: Use of selective estrogen modulators with progestationally active compounds for the treatment of estrogen-sensitive conditions

INVENTOR(S): Hodgen, Gary D.

PATENT ASSIGNEE(S): Medical College of Hampton Roads, USA

SOURCE: U.S., 4 pp., Cont.-in-part of U.S. Ser. No. 888,183,

abandoned.
CODEN: USXXAM

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6653297	B1	20031125	US 1998-59476	19980413 <--
EP 888775	A2	19990107	EP 1998-112107	19980701 <--
EP 888775	A3	20010502		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
CA 2268211	A1	19991013	CA 1999-2268211	19990401 <--
US 20030181431	A1	20030925	US 1999-313625	19990518 <--
US 7256185	B1	20070814	US 1999-313628	19990518 <--
PRIORITY APPLN. INFO.:			US 1997-888183	B2 19970703 <--
			US 1998-59476	A 19980413 <--


AB The treatment of an estrogen sensitive condition by the administration of a selective estrogen receptor modulator is improved by addnl. administering a progestationally active compound to the recipient. The addnl. agent can express both progestational and androgenic activity or an androgenically active material can be employed, if desired. Addnl., clomiphene in an array of isomeric ratios (EN:ZU) can be used alone for prevention of osteoporosis, maintenance of a healthful blood lipid profile, and prevention of breast tumors, or to sustain amenorrhea.

IT 17230-88-5, Danazol
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(selective estrogen modulators with progestationally active compds. for the treatment of estrogen-sensitive conditions)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 4 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:811173 HCAPLUS Full-text

DOCUMENT NUMBER: 139:312427

TITLE: Vagina-specific delivery preparation for treating gynopathy

INVENTOR(S): Chen, Guoshen; Chen, Liucun; Wang, Qiao

PATENT ASSIGNEE(S): Zhejiang Academy of Medical Sciences, Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 9 pp.

CODEN: CNXXEV

DOCUMENT TYPE: Patent
 LANGUAGE: Chinese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 1382444	A	20021204	CN 2002-111676	20020513 <--
PRIORITY APPLN. INFO.:			CN 2002-111676	20020513 <--

AB The vagina-specific delivery preparation (such as membrane or ointment) is composed of medicine, film-forming material or ointment matrix, and penetrating promoter. The medicine is danazol, mifepristone, gestrinone, medroxyprogesterone acetate, norethisterone, gonadoliberein synergist, gossypol, estriol, etc. The penetrating promoter is saturated or unsatd. fatty acid or its ester, polyethylene glycol, azone, surfactant, beta-cyclodextrin or its derivs., chelating agent, proteinase inhibitor, etc. The film-forming material is natural or synthetic high mol. material, etc. The ointment matrix is hydrocarbon, oil and fat, lipoid, etc. The vagina-specific delivery preparation may be used to treat ~~endometriosis~~, adenomyosis, infertility, senile vaginitis, etc.


IT 17230-88-5, Danazol

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (vaginal formulation for treating gynopathy)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 5 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:596559 HCAPLUS Full-text
 DOCUMENT NUMBER: 139:111684
 TITLE: Intrauterine formulations containing danazol and prostaglandin formation inhibitors for treatment of glandular ~~endometriosis~~
 INVENTOR(S): Igarashi, Masao
 PATENT ASSIGNEE(S): Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 4 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2003221338	A	20030805	JP 2002-19473	20020129 <--
PRIORITY APPLN. INFO.:			JP 2002-19473	20020129 <--


AB Intrauterine formulations containing danazol and prostaglandin formation inhibitors are claimed for treatment of glandular ~~endometriosis~~. The formulation containing danazol and diclofenac sodium was prepared and tested in patients with glandular ~~endometriosis~~.

IT 17230-88-5, Danazol
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (intrauterine formulations containing danazol and prostaglandin formation inhibitors for treatment of glandular ~~endometriosis~~)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 6 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:334653 HCAPLUS Full-text

DOCUMENT NUMBER: 138:343885

TITLE: Controlled release pharmaceuticals containing steroid complexes with cyclodextrin derivative

INVENTOR(S): Adeyeye, Christianah Moji; Jain, Ashwinkumar C.

PATENT ASSIGNEE(S): Duquesne University of the Holy Ghost, USA

SOURCE: U.S. Pat. Appl. Publ., 10 pp.
 CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030083309	A1	20030501	US 2001-934883	20010822 <--
US 6566347	B1	20030520		

PRIORITY APPLN. INFO.: US 2001-934883 20010822 <--

AB The present invention provides a controlled release pharmaceutical composition comprising a polydextrose, a drug that is complexed with the polydextrose, and a polymer matrix having the drug complexed with the polydextrose, wherein the polymer matrix and the polydextrose provide for a time release of the drug. A method of therapeutically treating a patient for an illness by employing the pharmaceutical composition is also provided. Danazol and sulfobutyl ether (SBE) of β -cyclodextrin (CD) were dissolved in 90% MeOH sep. and then the 2 solns. were mixed. The solns. were stirred at ambient temperature and evaporated to dryness. The resulting danazol-SBE β -CD complexes which are in the form of a white amorphous powder were screened through a sieve and stored in a desiccator.

IT 17230-88-5, Danazol
 RL: PKT (Pharmacokinetics); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (controlled release pharmaceuticals containing steroid complexes with


10/581,170

cyclodextrin derivative)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



IT 517866-43-2P

RL: PKT (Pharmacokinetics); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(controlled release pharmaceuticals containing steroid complexes with cyclodextrin derivative)

RN 517866-43-2 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)-, compd. with β -cyclodextrin 6A, 6B, 6C, 6D, 6E, 6F, 6G-heptakis(hydrogen sulfate) (9CI)
(CA INDEX NAME)


CM 1


CRN 184840-97-9

CMF C42 H70 O56 S7

Absolute stereochemistry. Rotation (+).

PAGE 1-A






CM 2

CRN 17230-88-5

CMF C22 H27 N O2

Absolute stereochemistry.



L15 ANSWER 7 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:927448 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 138:19526

TITLE: Nucleic acid-based modulation of VEGF/VEGF receptor genes, and use in the treatment and/or diagnosis of female reproductive diseases and angiogenesis-associated conditions

INVENTOR(S): Escobedo, Jaime; McSwiggen, James; Pavco, Pamela; Stinchcomb, Dan; Sandberg, Jennifer; Gordon, Gilad

PATENT ASSIGNEE(S): Ribozyme Pharmaceuticals, Incorporated, USA; Chiron Corporation

SOURCE: PCT Int. Appl., 172 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 267

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096927	A2	20021205	WO 2002-US17674	20020529 <--
WO 2002096927	A3	20030220		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

10/581,170

AU 9851819	A	19980611	AU 1998-51819	19980112 <--
AU 729657	B2	20010208		
AU 9939188	A	19990916	AU 1999-39188	19990713 <--
AU 769175	B2	20040115	AU 2000-56616	20000911 <--
US 20040077565	A1	20040422	US 2002-138674	20020503 <--
US 7034009	B2	20060425		
CA 2448320	A1	20021205	CA 2002-2448320	20020529 <--
AU 2002344237	A1	20021209	AU 2002-344237	20020529 <--
EP 1390385	A2	20040225	EP 2002-752028	20020529 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2005500025	T	20050106	JP 2003-500106	20020529 <--
US 20040102389	A1	20040527	US 2002-287949	20021104 <--
CA 2456444	A1	20030828	CA 2003-2456444	20030220 <--
WO 2003070910	A2	20030828	WO 2003-US5022	20030220 <--
WO 2003070910	A3	20050217		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003216323	A1	20030909	AU 2003-216323	20030220 <--
AU 2003216323	B2	20060413		
GB 2406569	A	20050406	GB 2004-27955	20030220 <--
GB 2406569	B	20050720		
EP 1521768	A2	20050413	EP 2003-742833	20030220 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU				
JP 2005517436	T	20050616	JP 2003-569803	20030220 <--
US 20040138163	A1	20040715	US 2003-665951	20030918 <--
US 20070203333	A1	20070830	US 2003-664668	20030918 <--
US 20040198682	A1	20041007	US 2003-683990	20031010 <--
US 20040220128	A1	20041104	US 2003-712633	20031113 <--
US 20040142895	A1	20040722	US 2003-726236	20031202 <--
US 20050075304	A1	20050407	US 2004-758155	20040112 <--
US 20050054596	A1	20050310	US 2004-764957	20040126 <--
US 20050148530	A1	20050707	US 2004-831620	20040423 <--
US 20050171039	A1	20050804	US 2004-844076	20040511 <--
US 7176304	B2	20070213		
US 20050267058	A1	20051201	US 2004-922761	20040820 <--
AU 2006203062	A1	20060810	AU 2006-203062	20060713 <--
AU 2006228026	A1	20061102	AU 2006-228026	20061011 <--
PRIORITY APPLN. INFO.:				
			US 2001-870161	A 20010529 <--
			US 2001-334461P	P 20011130 <--
			US 2002-138674	A 20020503 <--
			AU 1995-26422	A3 19950518 <--
			US 1995-5974P	P 19951026 <--
			US 1996-584040	A2 19960111 <--
			US 1996-623891	A 19960325 <--
			AU 1996-76662	A3 19961025 <--
			WO 1996-US17480	A 19961025 <--
			US 1999-371772	A2 19990810 <--
			US 2000-708690	A2 20001107 <--
			US 2001-292217P	P 20010518 <--
			US 2001-306883P	P 20010720 <--

US	2001-311865P	P	20010813	<--
US	2002-358580P	P	20020220	<--
US	2002-362016P	P	20020306	<--
US	2002-363124P	P	20020311	<--
WO	2002-US15876	A2	20020520	<--
WO	2002-US17674	W	20020529	<--
US	2002-386782P	P	20020606	<--
US	2002-393796P	P	20020703	<--
US	2002-399348P	P	20020729	<--
US	2002-406784P	P	20020829	<--
US	2002-408378P	P	20020905	<--
US	2002-409293P	P	20020909	<--
US	2002-287949	A	20021104	<--
US	2002-306747	A	20021127	<--
US	2003-440129P	P	20030115	<--
AU	2003-216323	A3	20030220	<--
AU	2003-219817	A3	20030220	<--
GB	2004-4898	A3	20030220	<--
WO	2003-US5022	W	20030220	<--
WO	2003-US5028	A2	20030220	<--
WO	2003-US5346	A2	20030220	<--
US	2003-427160	A2	20030430	<--
US	2003-444853	A2	20030523	<--
US	2003-665255	A2	20030916	<--
US	2003-664668	A2	20030918	<--
US	2003-665951	A2	20030918	<--
US	2003-670011	A2	20030923	<--
US	2003-683990	A2	20031010	<--
US	2003-693059	A2	20031023	<--
US	2003-712633	A2	20031113	<--
US	2003-720448	A2	20031124	<--
US	2003-726236	A2	20031202	<--
US	2003-727780	A2	20031203	
US	2004-758155	A2	20040112	
US	2004-757803	A2	20040114	
US	2004-764957	A2	20040126	
US	2004-543480P	P	20040210	
US	2004-780447	A2	20040213	
US	2004-826966	A2	20040416	
US	2004-831620	A2	20040423	
WO	2004-US13456	A2	20040430	
WO	2004-US16390	A2	20040524	

AB The invention discloses nucleic acid mols., including dsRNA, siRNA, antisense, 2,5-A chimeras, aptamers, and enzymic nucleic acid mols., such as hammerhead ribozymes, DNazymes, and allozymes, which modulate the expression of vascular endothelial growth factor receptor (VEGF) and/or vascular endothelial growth factor receptor (VEGFr) genes for the treatment and/or diagnosis of diseases and conditions associated with angiogenesis, such as cancer, tumor angiogenesis, or ocular indications such as diabetic retinopathy, or age-related macular degeneration, proliferative diabetic retinopathy, hypoxia-induced angiogenesis, rheumatoid arthritis, psoriasis, wound healing, and female reproductive disorders and conditions, including but not limited to ~~endometriosis~~, endometrial carcinoma, gynecol. bleeding disorders, irregular menstrual cycles, ovulation, premenstrual syndrome (PMS), and menopausal dysfunction.

IT 17230--88--5, Danazol

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(nucleic acid-based modulation of VEGF/VEGF receptor genes, use in treatment and/or diagnosis of female reproductive diseases and

angiogenesis-associated conditions, and use with other agents)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 8 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:792089 HCAPLUS Full-text

DOCUMENT NUMBER: 137:299928

TITLE: Pharmaceutical formulation for the treatment of
gynecological diseasesINVENTOR(S): Yui, Nobuhiko; Murakami, Kouichi; Ooya, Tooru; Sato,
Ikuo

PATENT ASSIGNEE(S): Chisso Corp., Japan

SOURCE: Eur. Pat. Appl., 10 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1249247	A2	20021016	EP 2002-7213	20020327 <--
EP 1249247	A3	20030115		
EP 1249247	B1	20070228		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2002356447	A	20021213	JP 2002-80018	20020322 <--
US 20020150605	A1	20021017	US 2002-108298	20020328 <--
US 7041310	B2	20060509		

PRIORITY APPLN. INFO.: JP 2001-100426 A 20010330 <--

AB This invention provides to a novel pharmaceutical formulation for the treatment of gynecol. diseases. The formulation comprises a drug for the intrauterine, intravaginal or intrapelvic administration, or for the administration into the ovarian endometrioma, and a biodegradable polymer comprising a chemical modified hyaluronic acid or a salt thereof prepared by O-acylating, alkoxylating or crosslinking a complex of hyaluronic acid or a salt thereof and a cationic compound in a nonaq. solvent. The preparation of the invention is preferably administered intrauterine, intravaginal, intrapelvic, and intratumor cavity. A suspension of distearyldimethylammonium chloride (DSC) in water was added to a solution of sodium hyaluronate (CHA) in water and the solution and the suspension were heated up to 45°. The resultant complex was recovered by centrifuging at 5000 rpm at room temperature and washed with warm water at 45°. After washing, the complex was lyophilized overnight and further vacuum-dried at 50° to give a CHA-DSC complex.

IT 17230-88-5, Danazol


10/581,170

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pharmaceutical formulation for treatment of gynecol. diseases)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 9 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:716096 HCAPLUS Full-text
 DOCUMENT NUMBER: 137:226651
 TITLE: Combined method for treating hormone-dependent disorders with aromatase inactivator exemestane and other therapeutic agents
 INVENTOR(S): Di Salle, Enrico; Piscitelli, Gabriella; Massimini, Giorgio; Purandare, Dinesh; Dekoning, Gans Hendrik
 PATENT ASSIGNEE(S): Pharmacia Italia S.p.A., Italy; Pharmacia & Upjohn Company
 SOURCE: PCT Int. Appl., 49 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072106	A2	20020919	WO 2002-EP638	20020118 <--
WO 2002072106	A3	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2434611	A1	20020919	CA 2002-2434611	20020118 <--
AU 2002257573	A1	20020924	AU 2002-257573	20020118 <--
EP 1377298	A2	20040107	EP 2002-727314	20020118 <--
EP 1377298	B1	20060830		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004519490	T	20040702	JP 2002-571065	20020118 <--
AT 337787	T	20060915	AT 2002-727314	20020118 <--
ES 2269682	T3	20070401	ES 2002-727314	20020118 <--
US 20040082557	A1	20040429	US 2003-611653	20030702 <--

PRIORITY APPLN. INFO.:

US 2001-770911 A 20010126 <--
 WO 2002-EP638 W 20020118 <--
 US 2002-393320P P 20020702 <--

AB A method of preventing and treating estrogen dependent disorders selected from endometriosis, uterine fibroids, dysfunctional uterine bleeding, endometrial hyperplasia, polycystic ovarian disease, fibrocystic breast disease and fibrocystic mastopathy, is disclosed which is comprised of administering to a mammalian patient in need of such treatment an effective amount of aromatase inactivator exemestane, alone or in combination with addnl. therapeutic agents.

IT 17230-88-5, Danazol


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)

(combined method for treating hormone-dependent disorders with
 aromatase inactivator exemestane and other therapeutic agents)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 10 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:293466 HCAPLUS Full-text

DOCUMENT NUMBER: 136:304093

TITLE: Compositions and methods for reducing GnRH-induced bone loss

INVENTOR(S): Quay, Steven C.

PATENT ASSIGNEE(S): Atossa Healthcare, Inc., USA

SOURCE: PCT Int. Appl., 35 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030451	A1	20020418	WO 2001-US31786	20011010 <--
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002013114	A5	20020422	AU 2002-13114	20011010 <--
PRIORITY APPLN. INFO.:			US 2000-686452	A 20001010 <--


AB Compns., and methods for administering such compns., are provided to reduce gonadotropin-releasing hormone (GnRH)-induced bone loss. The compns. are a pharmaceutically acceptable formulation comprising a therapeutically effective amount of GnRH and a bone growth promoting agent. The GnRH and bone growth promoting agent are typically formulated with a pharmaceutically acceptable carrier and administered in an amount sufficient to treat, to prevent, or to reduce the symptoms of, a sex steroid hormone-responsive condition in a patient. The GnRH and bone growth promoting agent can be administered prophylactically or to treat existing sex steroid hormone-responsive conditions in patients by a variety of administration modes, including i.m., i.v., intranasal, intrapulmonary, s.c., parenteral, oral, transmucosal or transdermal delivery modes.

IT 17230-88-5, Danazol
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compns. and methods for reducing GnRH-induced bone loss)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 11 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:222009 HCAPLUS Full-text
 DOCUMENT NUMBER: 134:242693
 TITLE: Compositions and methods for the prophylaxis and treatment of dysmenorrhea, ~~endometriosis~~, and pre-term labor, using histidine

INVENTOR(S): Peterson, John; Thomas, Peter G.
 PATENT ASSIGNEE(S): Cytos Pharmaceuticals LLC, USA
 SOURCE: U.S., 21 pp.
 CODEN: USXXAM

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 6207696	B1	20010327	US 1998-153354	19980915 <--
PRIORITY APPLN. INFO.:			US 1998-153354	19980915 <--

AB The present invention relates to methods and compns. for preventing or treating conditions or disorders of the female reproductive system by administering an effective dosage of histidine (500 mg-30 g daily) alone or in combination with other therapeutic agents, such as inhibitors of aromatase, prostaglandin synthase, or leukotriene biosynthesis, and antagonists of

10/581,170

activin and oxytocin receptors. The invention relates also to novel phys. compns. and delivery devices for administering histidine effectively to a female subject in need of either prophylaxis or treatment of certain disorders of the reproductive system. For example, a bioerodible intrauterine device and polycarbophil-based bioadhesive film containing L-histidine were prepared


IT 17230-88-5, Danazol

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. containing histidine for prophylaxis and treatment of female reproductive system disorders)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 12 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1998:527188 HCAPLUS [Full-text](#)

DOCUMENT NUMBER: 129:153247

ORIGINAL REFERENCE NO.: 129:31123a

TITLE: Pharmaceutical preparations and methods for their regional administration

INVENTOR(S): Ragavan, Vanaja V.; Dipiano, Gerianne M.

PATENT ASSIGNEE(S): Femmepharm, USA

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9832422	A1	19980730	WO 1998-US916	19980123 <--
W: AU, BR, CA, JP, KR, MX, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5993856	A	19991130	US 1997-971346	19971117 <--
CA 2278541	A1	19980730	CA 1998-2278541	19980123 <--
CA 2278541	C	20061024		
AU 9859227	A	19980818	AU 1998-59227	19980123 <--
AU 743157	B2	20020117		
EP 977555	A1	20000209	EP 1998-902614	19980123 <--
EP 977555	B1	20060329		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001511773	T	20010814	JP 1998-532060	19980123 <--
EP 1611878	A1	20060104	EP 2005-15104	19980123 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, FI

AT 321532	T	20060415	AT 1998-902614	19980123 <--
PT 977555	T	20060630	PT 1998-902614	19980123 <--
ES 2260828	T3	20061101	ES 1998-902614	19980123 <--
MX 9906819	A	20010531	MX 1999-6819	19990722 <--
US 6416778	B1	20020709	US 1999-355213	19990723 <--
US 20020172714	A1	20021121	US 2002-147762	20020516 <--
US 6652874	B2	20031125		

PRIORITY APPLN. INFO.:

US 1997-36727P	P	19970124 <--
US 1997-52578P	P	19970715 <--
US 1997-971346	A2	19971117 <--
EP 1998-902614	A3	19980123 <--
WO 1998-US916	W	19980123 <--
US 1999-355213	A1	19990723 <--

AB Formulations have been developed for regional delivery of drugs, for example, into a cavity such as the pelvic region, peritoneal region, or directly on organs of interest. Regional delivery increases comfort and bioavailability of the drug, resulting in rapid and relatively high blood levels in the regions to be treated in the substantial absence of side effects due to the high levels required for efficacy following systemic delivery. These formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The drug formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, cream, lotion, foam or suppository. Micronized danazol was levigated in a gel containing hydroxyethyl cellulose to deliver a dosage of 1 mg in 50 μ L. The microparticulate danazol 1 mg was delivered to the vaginal vault of rats to demonstrate a preferential absorption of danazol in to the uterus.

IT 17230-88-5, Danazol


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(micro or nanoparticles of drugs for their regional administration)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L15 ANSWER 13 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:85113 HCAPLUS Full-text

DOCUMENT NUMBER: 126:99321

ORIGINAL REFERENCE NO.: 126:19025a,19028a



TITLE: Methods for minimizing bone loss effects of anabolic agents by hydroxyphenylbenzothiophene derivatives

INVENTOR(S): Cullinan, George Joseph; Fontana, Steven Anthony

10/581,170

PATENT ASSIGNEE(S): Eli Lilly and Co., USA
 SOURCE: Eur. Pat. Appl., 11 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 747054	A2	19961211	EP 1996-304180	19960606 <--
EP 747054	A3	19970305		
EP 747054	B1	20020821		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
US 5599822	A	19970204	US 1995-467475	19950606 <--
CA 2223055	A1	19961212	CA 1996-2223055	19960605 <--
WO 9639138	A1	19961212	WO 1996-US8875	19960605 <--
W: AL, AM, AU, AZ, BB, BG, BR, BY, CA, CN, CZ, EE, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9660430	A	19961224	AU 1996-60430	19960605 <--
AU 696209	B2	19980903		
CN 1192145	A	19980902	CN 1996-195975	19960605 <--
BR 9608389	A	19990504	BR 1996-8389	19960605 <--
JP 11507051	T	19990622	JP 1997-501343	19960605 <--
HU 9900849	A2	19990928	HU 1999-849	19960605 <--
HU 9900849	A3	19991129		
ZA 9604778	A	19971208	ZA 1996-4778	19960606 <--
IL 118590	A	19991028	IL 1996-118590	19960606 <--
ES 2181849	T3	20030301	ES 1996-304180	19960606 <--
IN 1996CA01048	A	20050304	IN 1996-CA1048	19960606 <--
NO 9705581	A	19971203	NO 1997-5581	19971203 <--
PRIORITY APPLN. INFO.:			US 1995-467475	A 19950606 <--
			WO 1996-US8875	W 19960605 <--
OTHER SOURCE(S):		MARPAT 126:99321		
GI				




AB Method for minimizing the bone loss effect of I or a pharmaceutically acceptable salt thereof comprises concurrently or sequentially administering an effective amount of a compound of I [R1 = H, OH, O(C1-C4 alkyl), OCOC6H5, OCO(C1-C6 alkyl), or OSO2(C4-C6 alkyl); R2 = 1-piperidinyl, 1-pyrrolidinyl, methyl-1-pyrrolidinyl, dimethyl-1-pyrrolidinyl, 4-morpholino, dimethylamino, diethylamino, or 1-hexamethyleneimino] or a pharmaceutically acceptable salt thereof. Also provided is a method for minimizing bone loss induced by the administration of a formula II compound comprising concurrently or sequentially administering a bone anabolic agent. A pharmaceutical capsule contained raloxifene.HCl 50, starch 150, starch flowable powder 397, and silicone fluid 350 cSt 3.0 mg.

IT 17230-88-5, Danazol
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (minimizing bone loss effects of anabolic agents by hydroxyphenylbenzothiophene derivs.)

RN 17230-88-5 HCAPLUS

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17a)- (CA INDEX NAME)

Absolute stereochemistry.




L15 ANSWER 14 OF 31 HCAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1990:240497 HCAPLUS Full-text
 DOCUMENT NUMBER: 112:240497
 ORIGINAL REFERENCE NO.: 112:40463a,40466a
 TITLE: Topical drug delivery systems containing danazol
 INVENTOR(S): Igarashi, Masao
 PATENT ASSIGNEE(S): Japan
 SOURCE: Eur. Pat. Appl., 9 pp.
 CODEN: EPXXDW
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
EP 330786	A1	19890906	EP 1988-312441	19881230 <--
EP 330786	B1	19920318		
R: CH, DE, FR, GB, IT, LI, NL, SE				
JP 01221318	A	19890904	JP 1988-45928	19880301 <--
JP 2590358	B2	19970312		
US 4997653	A	19910305	US 1988-287481	19881220 <--
AU 8827479	A	19890907	AU 1988-27479	19881222 <--
AU 618052	B2	19911212		
CA 1312285	C	19930105	CA 1988-587300	19881230 <--

10/581,170

PRIORITY APPLN. INFO.: JP 1988-45928 A 19880301 <--
 AB A topical ~~drug delivery~~ system comprises a matrix base, danazol retained therein, and optionally a release promoting agent. This system is more effective than oral administration of danazol in the shrinkage of ~~endometriosis~~ tissue and the induction of pregnancy. It does not show any side effects that have been encountered in the oral administration of danazol. A vessel was charged with danazol 20, Silastic-382 75, and polysorbate 80 5 g. After the addition of 1.2 g of a tin catalyst the ingredients were mixed at room temperature for 20 min. The resulting mixture was poured into molds and solidified by allowing the molds to stand at room temperature for 1 day. The danazol content of these vaginal devices was 2100-2300 mg. In 46 patients who had been diagnosed with pelvic ~~endometriosis~~, a vaginal device was inserted into vagina. The size of ~~endometriosis~~ tissue in the uterine cul-de-sac was reduced to 0-0.5 cm2 by the 12-17th weeks in 44 cases.
 IT 17230-88-5, Danazol
 RL: BIOL (Biological study)
 (female reproductive organ disease treatment by topical administration of)
 RN 17230-88-5 HCAPLUS
 CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 15 OF 31 USPATFULL on STN
 ACCESSION NUMBER: 2006:282074 USPATFULL Full-text
 TITLE: Novel compounds with high therapeutic index
 INVENTOR(S): Chandran, V. Ravi, Allen, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060241017	A1	20061026
APPLICATION INFO.:	US 2006-343557	A1	20060130 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2004-US24901, filed on 29 Jul 2004, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2003-491331P	20030729 (60) <--
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCULLY SCOTT MURPHY & PRESSER, PC, 400 GARDEN CITY PLAZA, SUITE 300, GARDEN CITY, NY, 11530, US	
NUMBER OF CLAIMS:	39	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	8798	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 913339-63-6P 913339-64-7P

(preparation of amino acid derivs. with high therapeutic index)

RN 913339-63-6 USPTAFULL

CN L-Proline, (17 α)-pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-yl ester, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




● HCl

RN 913339-64-7 USPTAFULL

CN L-Proline, (17 α)-pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-yl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 17230-88-5, Danazol

(preparation of amino acid derivs. with high therapeutic index)

RN 17230-88-5 USPTAFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.




IT 913339-62-5P

(preparation of amino acid derivs. with high therapeutic index)

RN 913339-62-5 USPATFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, 1-(1,1-dimethylethyl)
(2S)-1,2-pyrrolidinedicarboxylate (ester), (17 α)- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.



L15 ANSWER 16 OF 31 USPATFULL on STN

ACCESSION NUMBER: 2005:227796 USPATFULL [Full-text](#)

TITLE: Vaginal ring preparation and its application

INVENTOR(S): Chen, Hai Lin, Shanghai, CHINA
Shao, Hai Hao, Shanghai, CHINA
Chen, Jian Xing, Shanghai, CHINA
Chen, Liang Kang, Shanghai, CHINA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050197651	A1	20050908
APPLICATION INFO.:	US 2005-72756	A1	20050304 (11)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-134402, filed on 25 Apr 2002, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	CN 2001-112712	20010425
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Joseph L. Strabala, Esq., Law Office of Joseph L. Strabala, Suite 1020, One Embarcadero Center, San Francisco, CA, 94111, US	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	382	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB A vaginal ~~drug delivery~~ device includes a tubular base of an inert rubber composition, a first layer having a thickness up to 3 mm composed of a mixture of a drug to delivered, at least one surfactant and at least one dispersing agent applied to said outer surface of the tubular base, and a second layer of silicone rubber having a thickness up to 1 mm encapsulating the first layer on the tubular base whereby said drug will diffuse through said second layer when the device is inserted into the vagina to treat the patient with the drug in the first layer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 17230-88-5, Danazol

(vaginal ring drug delivery device)

RN 17230-88-5 USPATFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 17 OF 31 USPATFULL on STN

ACCESSION NUMBER: 2005:3910 USPATFULL [Full-text](#)

TITLE: Drug

INVENTOR(S): Yui, Nobuhiko, Ishikawa, JAPAN
Murakami, Koichi, Ishikawa, JAPAN
Ooya, Tooru, Ishikawa, JAPAN
Sato, Ikuo, Kanagawa, JAPAN
Nakama, Tuyoshi, Ishikawa, JAPAN
Kawabata, Ryouji, Kanagawa, JAPAN

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20050003013	A1	20050106
APPLICATION INFO.:	US 2004-829243	A1	20040422 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	JP 2003-122861	20030425
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	WENDEROTH, LIND & PONACK, L.L.P., 2033 K STREET N. W., SUITE 800, WASHINGTON, DC, 20006-1021	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	2 Drawing Page(s)	
LINE COUNT:	756	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A drug is provided comprising of a degradable gel with a saturated moisture content not exceeding 98 weight % and a functional material, and which permits control of the rate of release of the functional material and

10/581,170

performs controlled-release of the functional material over a prolonged period of time, and wherein the gel itself decomposes and dissipates upon completion of release of the functional material.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 17230-88-5, Danazol

(sustained release polymer gels containing epoxy-crosslinked polysaccharides for moisture-controlled delivery of pharmaceuticals)

RN 17230-88-5 USPATFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 18 OF 31 USPATFULL on STN

ACCESSION NUMBER: 2004:326866 USPATFULL [Full-text](#)

TITLE: Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies

INVENTOR(S): Brunetta, Paul G., San Francisco, CA, UNITED STATES
Sliwowski, Mark X., San Carlos, CA, UNITED STATES

PATENT ASSIGNEE(S): GENENTECH, INC. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040258685	A1	20041223
APPLICATION INFO.:	US 2003-719310	A1	20031121 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-428027P	20021121 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	GENENTECH, INC., 1 DNA WAY, SOUTH SAN FRANCISCO, CA, 94080	
NUMBER OF CLAIMS:	46	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	12 Drawing Page(s)	
LINE COUNT:	3807	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present application describes treatment of non-malignant indications, such as psoriasis, ~~endometriosis~~, scleroderma, vascular diseases or disorders, respiratory disease, colon polyps or fibroadenoma, with anti-ErbB2 antibodies (e.g. rhuMab 2C4).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 17230-88-5, Danazol


(adjunct therapy with antibodies to ErbB2)

10/581,170

RN 17230-88-5 USPATFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 19 OF 31 USPATFULL on STN

ACCESSION NUMBER: 2004:320653 USPATFULL Full-text

TITLE: Sustained release formulations for nifedipine
dextromethorphan, and danazol

INVENTOR(S): Keller, Brian C., Antioch, CA, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 20040253306	A1	20041216
APPLICATION INFO.:	US 2004-889830	A1	20040712 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-136957, filed on 1 May 2002, PENDING		

	NUMBER	DATE	
	-----	-----	
PRIORITY INFORMATION:	US 2001-287992P	20010501 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
LINE COUNT:	501		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed herein are sustained release formulations of nifedipine and dextromethorphan that are compatible with a soft elastic gelatin capsule and a two-piece hard shell gelatin capsule. It has been discovered that specific lipids in the formulations can spontaneously form multilamellar liposomes upon introduction of the formulation to an aqueous environment. These spontaneously formed liposomes are stable under conditions that simulate the environment of the stomach and upper small intestine. The formulations can be administered orally, intra-ocularly, intranasally, rectally, or vaginally.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 17230-88-5, Danazol

(sustained-release formulations for nifedipine, dextromethorphan, or danazol capable of spontaneous formation of liposomes in aqueous environment)

RN 17230-88-5 USPATFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 20 OF 31 USPATFULL on STN

ACCESSION NUMBER: 2004:30724 USPATFULL Full-text

TITLE: Process for production of nanoparticles and microparticles by spray freezing into liquid

INVENTOR(S): Williams, Robert O., III, Austin, TX, UNITED STATES
 Johnston, Keith P., Austin, TX, UNITED STATES
 Young, Timothy J., Midland, MI, UNITED STATES
 Rogers, True L., Midland, MI, UNITED STATES
 Barron, Melisa K., San Francisco, CA, UNITED STATES
 Yu, Zhongshui, Austin, TX, UNITED STATES
 Hu, Jiahui, Austin, TX, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20040022861	A1	20040205
APPLICATION INFO.:	US 2002-273730	A1	20021018 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. WO 2002-US2894, filed on 30 Jan 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-345473P	20011019 (60)
	US 2001-264988P	20010130 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Tracey B. Davies, VINSON & ELKINS LLP, 2300 First City Tower, 1001 Fannin, Houston, TX, 77002-6760	
NUMBER OF CLAIMS:	35	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	29 Drawing Page(s)	
LINE COUNT:	2415	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a system and a method for the production of microparticles and nanoparticles of materials that can be dissolved. The system and method of the present invention provide quicker freezing times, which in turn produces a more uniform distribution of particle sizes, smaller particles, particles with increased porosity and a more intimate mixing of the particle components. The system and method of the present invention also produce particles with greater surface area than conventional methods. One form of the present invention provides a method for the preparation of particles. An effective ingredient is mixed with water, one or more solvents, or a combination thereof, and the resulting mixture is sprayed through an insulating nozzle located at or below the level of a cryogenic liquid. The spray generates frozen particles.

10/581,170

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 17230-88-5, Danazol

(production of nanoparticles and microparticles by spray freezing into liquid)

RN 17230-88-5 USPATFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 21 OF 31 USPATFULL on STN

ACCESSION NUMBER: 2003:257316 USPATFULL Full-text

TITLE: Bioadhesive drug delivery system

INVENTOR(S): Kirschner, Mitchell I., St. Louis, MO, UNITED STATES

Levinson, R. Saul, Chesterfield, MO, UNITED STATES

Riley, Thomas C., Manchester, MO, UNITED STATES

Hermelin, Marc S., St. Louis, MO, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20030180366	A1	20030925	<--
	US 6899890	B2	20050531	
APPLICATION INFO.:	US 2002-101014	A1	20020320	(10)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	NATH & ASSOCIATES, 1030 15th STREET, 6TH FLOOR,			
	WASHINGTON, DC, 20005			
NUMBER OF CLAIMS:	57			
EXEMPLARY CLAIM:	1			
LINE COUNT:	1278			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to a novel essentially pH neutral vaginal drug delivery system suitable for modified delivery of a therapeutically active material in the vaginal cavity. The vaginal drug delivery system comprises an essentially pH neutral emulsion having globules having two phases, an internal water soluble phase and an external water-insoluble phase or film, wherein the water-soluble interior phase contains a therapeutically active drug or drugs. One novel aspect of the vaginal drug delivery system is that the internal water soluble phase comprises an acidic buffered phase.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 17230-88-5, Danazol

(bioadhesive vaginal drug delivery system containing acidic buffer)

RN 17230-88-5 USPATFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 22 OF 31 USPTF on STN

ACCESSION NUMBER: 2003:61496 USPTF Full-text

TITLE: Process for production of nanoparticles and microparticles by spray freezing into liquid

INVENTOR(S): Williams, Robert O., III, Austin, TX, UNITED STATES
 Johnston, Keith P., Austin, TX, UNITED STATES
 Young, Timothy J., Midland, MI, UNITED STATES
 Rogers, True L., Austin, TX, UNITED STATES
 Barron, Melisa K., Conroe, TX, UNITED STATES
 Yu, Zhongshui, Austin, TX, UNITED STATES
 Hu, Jiahui, Austin, TX, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20030041602	A1	20030306	<--
	US 6862890	B2	20050308	
APPLICATION INFO.:	US 2002-62648	A1	20020130	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-264988P	20010130	(60) <--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	THE DOW CHEMICAL COMPANY, INTELLECTUAL PROPERTY SECTION, P. O. BOX 1967, MIDLAND, MI, 48641-1967		
NUMBER OF CLAIMS:	22		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		
LINE COUNT:	905		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a system and a method for the production of microparticles and nanoparticles of materials that can be dissolved. The system and method of the present invention provide quicker freezing times, which in turn produces a more uniform distribution of particle sizes, smaller particles, particles with increased porosity and a more intimate mixing of the particle components. The system and method of the present invention also produce particles with greater surface area than conventional methods. One form of the present invention provides a method for the preparation of particles. An effective ingredient is mixed with water, one or more solvents, or a combination thereof, and the resulting mixture is sprayed through an insulating nozzle located at or below the level of a cryogenic liquid. The spray generates frozen particles.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 17230-88-5, Danazol

(production of nanoparticles and microparticles by spray freezing into liquid)

10/581,170

RN 17230-88-5 USPATFULL
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 23 OF 31 USPATFULL on STN
ACCESSION NUMBER: 2003:3110 USPATFULL Full-text
TITLE: Sustained release formulations for nifedipine,
dextromethorphan, and danazol
INVENTOR(S): Keller, Brian C., Antioch, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20030003144	A1	20030102	<--
APPLICATION INFO.:	US 2002-136957	A1	20020501 (10)	

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2001-287992P	20010501 (60)	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Bruce D. Grant, Morrison & Foerster LLP, Suite 500, 3811 Valley Centre Drive, San Diego, CA, 92130-2332		
NUMBER OF CLAIMS:	30		
EXEMPLARY CLAIM:	1		
LINE COUNT:	495		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Disclosed herein are sustained release formulations of nifedipine and dextromethorphan that are compatible with a soft elastic gelatin capsule and a two-piece hard shell gelatin capsule. It has been discovered that specific lipids in the formulations can spontaneously form multilamellar liposomes upon introduction of the formulation to an aqueous environment. These spontaneously formed liposomes are stable under conditions that simulate the environment of the stomach and upper small intestine. The formulations can be administered orally, intra-ocularly, intranasally, rectally, or vaginally.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 17230-88-5, Danazol
(sustained-release formulations for nifedipine, dextromethorphan, or danazol capable of spontaneous formation of liposomes in aqueous environment)

RN 17230-88-5 USPATFULL
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 24 OF 31 USPATFULL on STN

ACCESSION NUMBER: 2002:307595 USPATFULL Full-text

TITLE: Pharmaceutical preparations and methods for their regional administration

INVENTOR(S): DiPiano, Gerianne, Malvern, PA, UNITED STATES
Ragavan, Vanaja V., Wynnewood, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20020172714	A1	20021121	<--
	US 6652874	B2	20031125	
APPLICATION INFO.:	US 2002-147762	A1	20020516	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-355213, filed on 23 Jul 1999, GRANTED, Pat. No. US 6416778 A 371 of International Ser. No. WO 1998-US916, filed on 23 Jan 1998, UNKNOWN Continuation-in-part of Ser. No. US 1997-971346, filed on 17 Nov 1997, GRANTED, Pat. No. US 5993856			

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1997-36727P	19970124	(60) <--
	US 1997-52578P	19970715	(60) <--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	PATREA L. PABST, HOLLAND & KNIGHT LLP, SUITE 2000, ONE ATLANTIC CENTER, 1201 WEST PEACHTREE STREET, N.E., ATLANTA, GA, 30309-3400		
NUMBER OF CLAIMS:	33		
EXEMPLARY CLAIM:	1		
LINE COUNT:	546		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Formulations have been developed for regional delivery of drugs, for example, into a cavity such as the pelvic region, peritoneal region, or directly on organs of interest. Regional delivery increases comfort and bioavailability of the drug, resulting in rapid and relatively high blood levels in the regions to be treated in the substantial absence of side effects due to the high levels required for efficacy following systemic delivery. In the preferred embodiment, these formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The drug formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 17230-88-5, Danazol


10/581,170

(micro or nanoparticles of drugs for their regional administration)

RN 17230-88-5 USPATFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 25 OF 31 USPATFULL on STN

ACCESSION NUMBER: 2002:288478 USPATFULL Full-text

TITLE: Vaginal ring preparation and application

INVENTOR(S): Lin, Chen Hai, Shanghai, CHINA

Hao, Shao Hai, Shanghai, CHINA

Xing, Chen Jian, Shanghai, CHINA

Kang, Chen Liang, Shanghai, CHINA

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20020161352	A1	20021031	<--
APPLICATION INFO.:	US 2002-134402	A1	20020425 (10)	

	NUMBER	DATE	
PRIORITY INFORMATION:	CN 2001-112712	20010425	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Joseph L. Strabala, Esq, Law Offices of Joseph L. Strabala, Suite 1020, One Embarcadero Center, San Francisco, CA, 94111		
NUMBER OF CLAIMS:	10		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	2 Drawing Page(s)		
LINE COUNT:	346		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A vaginal ~~drug delivery~~ device includes a tubular base of an inert rubber composition, a first layer having a thickness up to 3 mm composed of a mixture of a drug to delivered, at least one surfactant and at least one dispersing agent applied to said outer surface of the tubular base, and a second layer of silicone rubber having a thickness up to 1 mm encapsulating the first layer on the tubular base whereby said drug will diffuse through said second layer when the device is inserted into the vagina to treat the patient with the drug in the first layer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 17230-88-5, Danazol

(vaginal ring preparation and application)

RN 17230-88-5 USPATFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 26 OF 31 USPATFULL on STN

ACCESSION NUMBER: 2002:272490 USPATFULL Full-textTITLE: Pharmaceutical preparation for the treatment of
gynecological diseasesINVENTOR(S): Yui, Nobuhiko, Ishikawa-ken, JAPAN
Murakami, Kouichi, Kanazawa-shi, JAPAN
Ooya, Tooru, Ishikawa-ken, JAPAN
Sato, Ikuo, Yokohama-shi, JAPAN

PATENT ASSIGNEE(S): Yui, Nobuhiko, Ishikawa-ken, JAPAN (U.S. individual)

	NUMBER	KIND	DATE	
	-----	----	-----	
PATENT INFORMATION:	US 20020150605	A1	20021017	<--
	US 7041310	B2	20060509	
APPLICATION INFO.:	US 2002-108298	A1	20020328	(10)

	NUMBER	DATE	
	-----	-----	
PRIORITY INFORMATION:	JP 2001-100426	20010330	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	LEYDIG VOIT & MAYER, LTD, 700 THIRTEENTH ST. NW, SUITE 300, WASHINGTON, DC, 20005-3960		
NUMBER OF CLAIMS:	20		
EXEMPLARY CLAIM:	1		
LINE COUNT:	754		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides to a novel pharmaceutical preparation for the treatment of gynecological diseases. The pharmaceutical preparation according to the invention comprises a therapeutic drug for the intrauterine, intravaginal or intrapelvic administration, or for the administration into the ovarian endometrioma, and a biodegradable polymer comprising a chemically modified hyaluronic acid or a salt thereof prepared by O-acylating, alkoxylating or crosslinking a complex of hyaluronic acid or a salt thereof and a cationic compound in a nonaqueous solvent. The preparation of the invention is preferably administered intrauterine, intravaginal, intrapelvic, and intratumor cavity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 17230-88-5, Danazol

(pharmaceutical formulation for treatment of gynecol. diseases)

RN 17230-88-5 USPATFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 27 OF 31 USPATFULL on STN

ACCESSION NUMBER: 2002:167901 USPATFULL Full-text

TITLE: Pharmaceutical preparations and methods for their regional administration

INVENTOR(S): Ragavan, Vanaja V., Wynnewood, PA, United States
DiPiano, Gerianne M., Malvern, PA, United States

PATENT ASSIGNEE(S): FemmePharma, Wayne, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6416778	B1	20020709	<--
	WO 9832422		19980730	<--
APPLICATION INFO.:	US 1999-355213		19990723	(9)
	WO 1998-US916		19980123	
			19990723	PCT 371 date

	NUMBER	DATE	
PRIORITY INFORMATION:	US 1997-36727P	19970124	(60) <--
	US 1997-52578P	19970715	(60) <--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	GRANTED		
PRIMARY EXAMINER:	Spear, James M.		
LEGAL REPRESENTATIVE:	Pabst, Patrea L., Holland & Knight LLP		
NUMBER OF CLAIMS:	26		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)		
LINE COUNT:	628		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Formulations have been developed for regional delivery of drugs, for example, into a cavity such as the pelvic region, peritoneal region, or directly on organs of interest. Regional delivery increases comfort and bioavailability of the drug, resulting in rapid and relatively high blood levels in the regions to be treated in the substantial absence of side effects due to the high levels required for efficacy following systemic delivery. In the preferred embodiment, these formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The drug formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 17230-88-5, Danazol

(micro or nanoparticles of drugs for their regional administration)

10/581,170

RN 17230-88-5 USPATFULL
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 28 OF 31 USPATFULL on STN
ACCESSION NUMBER: 1999:155240 USPATFULL Full-text
TITLE: Pharmaceutical preparations and methods for their administration
INVENTOR(S): Ragavan, Vanaja V., Wynnewood, PA, United States
DiPiano, Gerrienne M., Malvern, PA, United States
PATENT ASSIGNEE(S): FemmePharma, Wayne, PA, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5993856		19991130	<--
APPLICATION INFO.:	US 1997-971346		19971117	(8)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Mosley, Terressa			
LEGAL REPRESENTATIVE:	Arnall Golden & Gregory, LLP			
NUMBER OF CLAIMS:	33			
EXEMPLARY CLAIM:	1			
LINE COUNT:	675			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


AB Formulations which have been developed for topical or local delivery intrapelvically, intraperitoneally or directly on reproductive organs of interest administration to a region such as the female reproductive system, provide for increased comfort, increased bioavailability, rapid and relatively high blood levels in the regions to be treated in the substantial absence of systemic levels of drug which might cause side effects. These formulations consist of drug micro or nanoparticles, which may be formed of drug alone or in combination with an excipient or polymeric carrier. The excipient or polymer may be used to manipulate release rates and to increase adhesion to the affected region. The particulate formulation can be applied as a dried powder, a liquid suspension or dispersion, or as a topical ointment, creme, lotion, foam or suppository.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 17230-88-5, Danazol
(micro or nanoparticles of drugs for their regional administration)

RN 17230-88-5 USPATFULL
CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 29 OF 31 USPATFULL on STN

ACCESSION NUMBER: 94:73073 USPATFULL Full-text

TITLE: Method and formulations for use in treating benign gynecological disorders

INVENTOR(S): Pike, Malcolm C., Long Beach, CA, United States
Spicer, Darcy V., Pasadena, CA, United States

PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA,
United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5340585		19940823 <--
APPLICATION INFO.:	US 1993-62883		19930517 (8)
DISCLAIMER DATE:	20100518		
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1992-952513, filed on 3 Dec 1992 which is a continuation-in-part of Ser. No. US 1991-684612, filed on 12 Apr 1991, now patented, Pat. No. US 5211952		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Page, Thurman K.		
ASSISTANT EXAMINER:	Azpuru, Carlos		
LEGAL REPRESENTATIVE:	Robbins, Berliner & Carson		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
LINE COUNT:	901		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods which are effective to treat benign gynecological disorders for extended periods of time in women in who the risk of endometrial stimulation is minimized or absent are described, wherein an effective amount of a gonadotropin hormone releasing hormone composition and an effective amount of an estrogenic composition are provided over a period of time, optionally with addition of an androgenic composition.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.


IT 17230-88-5, Danazol

(GnRH composition and estrogenic composition combination for treatment of benign gynecol. disorders)

RN 17230-88-5 USPATFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 30 OF 31 USPATFULL on STN

ACCESSION NUMBER: 94:73072 USPATFULL Full-text

TITLE: Methods and formulations for use in inhibiting conception and in treating benign gynecological disorders

INVENTOR(S): Spicer, Darcy V., Pasadena, CA, United States
Pike, Malcolm C., Long Beach, CA, United States

PATENT ASSIGNEE(S): University of Southern California, Los Angeles, CA,
United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 5340584		19940823	<--
APPLICATION INFO.:	US 1993-952513		19930201	(7)
	WO 1992-US2973		19920410	
			19930201	PCT 371 date
			19930201	PCT 102(e) date
DISCLAIMER DATE:	20100518			
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1991-684612, filed on 12 Apr 1991, now abandoned			
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	Granted			
PRIMARY EXAMINER:	Page, Thurman K.			
ASSISTANT EXAMINER:	Azpuru, Carlos			
LEGAL REPRESENTATIVE:	Robbins, Berliner & Carson			
NUMBER OF CLAIMS:	32			
EXEMPLARY CLAIM:	1			
LINE COUNT:	1022			
CAS INDEXING IS AVAILABLE FOR THIS PATENT.				

AB Compositions and methods which are effective to inhibit conception and to treat benign gynecological disorders for extended periods of time are described, wherein an effective amount of a gonadotropin hormone releasing hormone composition and an effective amount of an estrogenic composition are provided over a first period of time, in addition to a progestogen and optionally an androgenic composition. According to one protocol, the progestogen is provided for a second, shorter period of time; the progestogen is provided at a higher level for at least 5 to about 20 days, and then at a lower level for the remainder, if any, of the second period of time. In an alternative protocol, the progestogen is provided at a lower level substantially throughout the period of administration of gonadotropin hormone releasing hormone composition and estrogenic composition. An effective amount of the androgenic hormone is optionally provided over the first period of time.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 17230-88-5, Danazol

(contraceptive slow-release pharmaceuticals containing gonadotropin hormone


10/581,170

releasing hormone and, as androgen)

RN 17230-88-5 USPATFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

Absolute stereochemistry.



L15 ANSWER 31 OF 31 USPATFULL on STN

ACCESSION NUMBER: 91:18771 USPATFULL Full-text

TITLE: Method for treating ~~endometriosis~~ with
topical preparations containing danazol

INVENTOR(S): Igarashi, Masao, 357-4, Hiyoshi-cho H-chome,
Maebashi-shi, Gunma, Japan

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 4997653		19910305	<--
APPLICATION INFO.:	US 1988-287481		19881220	(7)

	NUMBER	DATE	
PRIORITY INFORMATION:	JP 1988-45928	19880301	<--
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Lee, Lester L.		
ASSISTANT EXAMINER:	Pili-Curtis, Carmen		
LEGAL REPRESENTATIVE:	McGlew & Tuttle		
NUMBER OF CLAIMS:	8		
EXEMPLARY CLAIM:	1		
LINE COUNT:	454		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A topical preparation of danazol comprising a matrix base, danazol retained therein, and optionally a release-promoting agent is provided.

The topical preparation is more effective than oral administration of danazol in the shrinkage of ~~endometriosis~~ tissue, the induction of pregnancy, and the like. It does not show any side effects that have been encountered in the oral administration of danazol. Thus, the preparation is very useful remedy for ~~endometriosis~~.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

IT 17230-88-5, Danazol


(female reproductive organ disease treatment by topical administration
of)

RN 17230-88-5 USPATFULL

CN Pregna-2,4-dien-20-yno[2,3-d]isoxazol-17-ol, (17 α)- (CA INDEX NAME)

10/581,170

Absolute stereochemistry.



SEARCH HISTORY

=> d his ful

(FILE 'HOME' ENTERED AT 11:17:06 ON 15 OCT 2008)

FILE 'HCAPLUS' ENTERED AT 11:17:15 ON 15 OCT 2008

E HOLM PER/AU

L1 81 SEA ABB=ON ("HOLM PER"/AU OR "HOLM PER S"/AU OR "HOLM PER
SONNE"/AU)

E NORLING TOMAS/AU

L2 31 SEA ABB=ON ("NORLING T"/AU OR "NORLING TOMAS"/AU)

L3 21 SEA ABB=ON L1 AND L2

L4 1 SEA ABB=ON L3 AND ?DANAZOL?
SELECT RN L4 1

FILE 'REGISTRY' ENTERED AT 11:17:54 ON 15 OCT 2008

L5 21 SEA ABB=ON (106392-12-5/BI OR 109-43-3/BI OR 12511-31-8/BI OR
1318-93-0/BI OR 1327-43-1/BI OR 1343-98-2/BI OR 14987-04-3/BI
OR 17230-88-5/BI OR 25322-68-3/BI OR 33434-24-1/BI OR 357271-96
-6/BI OR 63-42-3/BI OR 66732-77-2/BI OR 736175-62-5/BI OR
7631-86-9/BI OR 77-93-0/BI OR 9002-89-5/BI OR 9003-39-8/BI OR
9004-32-4/BI OR 9004-57-3/BI OR 9004-65-3/BI)

FILE 'HCAPLUS' ENTERED AT 11:17:58 ON 15 OCT 2008

L6 1 SEA ABB=ON L4 AND L5

FILE 'REGISTRY' ENTERED AT 11:19:09 ON 15 OCT 2008

L7 STRUCTURE 17230-88-5

L8 3 SEA SSS SAM L7

L9 36 SEA SSS FUL L7

FILE 'HCAPLUS' ENTERED AT 11:19:24 ON 15 OCT 2008

L10 893 SEA ABB=ON L9

L11 135 SEA ABB=ON L10 AND ?ENDOMETRIOSIS?

L12 20 SEA ABB=ON L11 AND ?DRUG?(W)?DELIVER?

FILE 'USPATFULL' ENTERED AT 11:21:04 ON 15 OCT 2008

L13 19 SEA ABB=ON L11 AND ?DRUG?(W)?DELIVER?

FILE 'HCAPLUS, USPATFULL' ENTERED AT 11:21:14 ON 15 OCT 2008

L14 39 DUP REMOV L12 L13 (0 DUPLICATES REMOVED)

L15 31 SEA ABB=ON L14 AND (PRD<20031203 OR PD<20031203)

FILE HOME

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Oct 2008 VOL 149 ISS 16

10/581,170

FILE LAST UPDATED: 14 Oct 2008 (20081014/ED)

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 14 OCT 2008 HIGHEST RN 1061458-09-0
DICTIONARY FILE UPDATES: 14 OCT 2008 HIGHEST RN 1061458-09-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

FILE USPATFULL

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 14 Oct 2008 (20081014/PD)
FILE LAST UPDATED: 14 Oct 2008 (20081014/ED)
HIGHEST GRANTED PATENT NUMBER: US7437772
HIGHEST APPLICATION PUBLICATION NUMBER: US20080250537
CA INDEXING IS CURRENT THROUGH 14 Oct 2008 (20081014/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 14 Oct 2008 (20081014/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Aug 2008
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Aug 2008

USPATFULL now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.